Latest Europe News

Advanced Innergy Holdings Ltd (ASX:AIH) has reported a robust FY25 performance highlighted by a successful IPO and strong growth across its core segments, setting a confident tone for FY26.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Ramsay Health Care is set to simplify its corporate structure by distributing its majority stake in European healthcare provider Ramsay Santé directly to shareholders, enabling focused growth strategies for both entities.

Tungsten Mining has secured $53 million to push its Mt Mulgine Project through critical feasibility stages while engaging international partners for processing and offtake. The company is positioning itself as a key player in the global tungsten market with strategic moves in the US and Europe.

Little Green Pharma has entered a $7.8 million sale and leaseback agreement for its Western Australia production site, aiming to fuel growth in Australia and Europe while maintaining operational control.

Medical Developments International (MVP) reported an 8% revenue increase driven by strong Penthrox growth, despite a slight EBIT loss impacted by foreign exchange. The company advances pediatric approvals and targets further volume gains.

Enero Group’s half-year results reveal a 6.3% revenue decline but a striking 119% surge in adjusted profit, alongside strategic leadership changes and a steady dividend.

Aristocrat Leisure reported robust FY25 results with double-digit revenue and profit growth, underpinned by strategic divestments and investments in AI. The company’s FY26 outlook remains positive, driven by market share gains and new product launches.

Goodman Group reported a slight dip in operating profit for the half year ended 31 December 2025, while statutory profit rose and the total portfolio value expanded to $87.4 billion. The group maintained its interim distribution at 15 cents per security amid ongoing investment in logistics and digital infrastructure.

Australian Vintage reports steady first-half sales and outlines a robust strategy focused on innovation, portfolio diversification, and global expansion to meet full-year growth targets.

Brambles Limited reported a 5% rise in sales revenue and a 7% increase in underlying profit for the half-year ended December 2025, alongside a raised interim dividend. The company navigated volume declines with price realisation and productivity gains, while advancing sustainability goals.